Plain-English translation of NCT05952947 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called , which is a type of cell therapy designed to fight cancers caused by HPV18 infection. Researchers will take immune cells from your blood, train them in the laboratory to recognize and attack HPV18-infected cancer cells, and then put them back into your body. The study wants to understand whether this treatment is safe and whether it helps shrink tumors.
Many people with HPV18-related cancers have already tried other treatments that didn't work or stopped working. This medication is being developed because there is a need for new treatment options for patients who have limited choices left.
You likely qualify if…
You likely don't qualify if…
You will first undergo a procedure called lymphocytapheresis, in which doctors use a machine to collect immune cells from your blood (similar to blood donation). Your cells will then be sent to a laboratory where they are treated and grown to recognize HPV18-infected cancer cells. After several weeks, the cells will be given back to you through an infusion. You will be monitored closely for side effects and to see whether your tumors respond to the treatment.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
HRYZ Biotech Co.
Enrollment target
~32 participants
Started
November 2023
Primary completion
December 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in February 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xuemin Rao
Fudan University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.